Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis [0.03%]
慢性偏头痛患者使用艾尔建公司恩拉莫普单抗与onabotulinumtoxinA的比较分析研究
María Garcés-Pellejero,Marta Torres-Ferrús,Rut Mas-de-Les-Valls et al.
María Garcés-Pellejero et al.
Objectives: To compare response (reduction in headache frequency and differences in patient-reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase-IV trials after 6 months of treatment. ...
Comparative Study
European journal of neurology. 2026 Jun;33(6):e70654. DOI:10.1111/ene.70654 2026
Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations [0.03%]
妊娠期间管理庞贝病和酶替代治疗的挑战与考虑因素
Maudy T M Theunissen,Zohra Hayat,Françoise Bouhour et al.
Maudy T M Theunissen et al.
Background: There are no clear guidelines for enzyme replacement therapy (ERT) use and obstetric management in pregnant patients with Pompe disease receiving ERT. This study aims to explore outcomes and challenges for the...
Quantitative Neuromuscular MRI in CIDP Patients: Interest of a Multiparametric Approach [0.03%]
CIDP患者的定量神经肌肉磁共振成像：多参数方法的应用价值
A Guérémy,E Fortanier,C P Michel et al.
A Guérémy et al.
Objective: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by heterogeneous clinical presentations and the absence of validated imaging biomarkers. Although several quantitative MRI (qMRI...
The Electrophysiology of Disease Remission in Chronic Inflammatory Demyelinating Polyneuropathy [0.03%]
慢性炎症性脱髓鞘多发性神经病缓解期的电生理学特征
Yusuf A Rajabally,Joumana Freiha,Roshan Iqbal et al.
Yusuf A Rajabally et al.
Background: Whether serial electrophysiology may be useful in chronic inflammatory demyelinating polyneuropathy (CIDP), in remission off treatment, is unknown. ...
Who Falls After a Stroke? Evidence From a Prospective Stroke Cohort [0.03%]
哪类患者发生卒中后会跌倒？来自前瞻性卒中队列的证据
Anna Kufner,Yunyou Tang,Uchralt Temuulen et al.
Anna Kufner et al.
Background: Falls affect over 30% of stroke survivors within the first year, yet lesion-related mobility and gait impairments underlying fall risk remain poorly understood. This study aimed to identify lesion-derived func...
Multicenter Study
European journal of neurology. 2026 Jun;33(6):e70678. DOI:10.1111/ene.70678 2026
Risk of Clinical Events in Presymptomatic Familial Cerebral Cavernous Malformations [0.03%]
无症状型家族性脑 cavernous 病变患者的临床事件发生风险
Constantina Rodica Popa,Dominique Hervé,Nassira Alili et al.
Constantina Rodica Popa et al.
Background and purpose: Familial cerebral cavernous malformations (fCCM) may cause focal neurological deficits (FND) due to hemorrhagic or non-hemorrhagic events and epileptic seizures (ES). With the widespread use of mag...
Tolerability, Safety and Effectiveness of Sigh Introduction During Non-Invasive Mechanical Ventilation Cycles in Patients With Amyotrophic Lateral Sclerosis [0.03%]
非侵袭性机械通气期间引入叹息样呼吸对肌萎缩侧索硬化患者的耐受性、安全性及有效性研究
Nilo Riva,Paride Schito,Tommaso Russo et al.
Nilo Riva et al.
Background: Respiratory failure is the main cause of death in Amyotrophic lateral sclerosis (ALS), in which the physiological sigh reflex is impaired due to inspiratory muscle weakness. Aim of this study is to assess the ...
Randomized Controlled Trial
European journal of neurology. 2026 Jun;33(6):e70660. DOI:10.1111/ene.70660 2026